nodes	percent_of_prediction	percent_of_DWPC	metapath
Rizatriptan—CYP1A2—Efavirenz—acquired immunodeficiency syndrome	0.106	0.197	CbGbCtD
Rizatriptan—CYP1A2—Nevirapine—acquired immunodeficiency syndrome	0.0993	0.185	CbGbCtD
Rizatriptan—CYP1A2—Lopinavir—acquired immunodeficiency syndrome	0.0993	0.185	CbGbCtD
Rizatriptan—CYP1A2—Delavirdine—acquired immunodeficiency syndrome	0.0898	0.167	CbGbCtD
Rizatriptan—CYP1A2—Nelfinavir—acquired immunodeficiency syndrome	0.0753	0.14	CbGbCtD
Rizatriptan—CYP1A2—Ritonavir—acquired immunodeficiency syndrome	0.0681	0.127	CbGbCtD
Rizatriptan—MAOA—nerve—acquired immunodeficiency syndrome	0.00334	0.0876	CbGeAlD
Rizatriptan—HTR1A—blood plasma—acquired immunodeficiency syndrome	0.00276	0.0725	CbGeAlD
Rizatriptan—MAOA—blood plasma—acquired immunodeficiency syndrome	0.00253	0.0663	CbGeAlD
Rizatriptan—HTR1F—nervous system—acquired immunodeficiency syndrome	0.00249	0.0652	CbGeAlD
Rizatriptan—HTR1F—central nervous system—acquired immunodeficiency syndrome	0.00239	0.0628	CbGeAlD
Rizatriptan—CYP1A2—blood plasma—acquired immunodeficiency syndrome	0.00211	0.0553	CbGeAlD
Rizatriptan—HTR1F—brain—acquired immunodeficiency syndrome	0.0019	0.0499	CbGeAlD
Rizatriptan—MAOA—retina—acquired immunodeficiency syndrome	0.00138	0.0363	CbGeAlD
Rizatriptan—HTR1B—spinal cord—acquired immunodeficiency syndrome	0.00121	0.0317	CbGeAlD
Rizatriptan—HTR1B—nervous system—acquired immunodeficiency syndrome	0.00102	0.0267	CbGeAlD
Rizatriptan—HTR1D—nervous system—acquired immunodeficiency syndrome	0.000986	0.0259	CbGeAlD
Rizatriptan—HTR1B—central nervous system—acquired immunodeficiency syndrome	0.000981	0.0257	CbGeAlD
Rizatriptan—HTR1A—spinal cord—acquired immunodeficiency syndrome	0.000976	0.0256	CbGeAlD
Rizatriptan—MAOA—digestive system—acquired immunodeficiency syndrome	0.000971	0.0255	CbGeAlD
Rizatriptan—HTR1D—central nervous system—acquired immunodeficiency syndrome	0.000949	0.0249	CbGeAlD
Rizatriptan—MAOA—blood—acquired immunodeficiency syndrome	0.000925	0.0243	CbGeAlD
Rizatriptan—MAOA—spinal cord—acquired immunodeficiency syndrome	0.000891	0.0234	CbGeAlD
Rizatriptan—MAOA—vagina—acquired immunodeficiency syndrome	0.000857	0.0225	CbGeAlD
Rizatriptan—HTR1A—nervous system—acquired immunodeficiency syndrome	0.000822	0.0216	CbGeAlD
Rizatriptan—MAOA—lung—acquired immunodeficiency syndrome	0.000811	0.0213	CbGeAlD
Rizatriptan—CYP1A2—digestive system—acquired immunodeficiency syndrome	0.00081	0.0213	CbGeAlD
Rizatriptan—HTR1A—central nervous system—acquired immunodeficiency syndrome	0.000791	0.0208	CbGeAlD
Rizatriptan—HTR1B—brain—acquired immunodeficiency syndrome	0.000779	0.0204	CbGeAlD
Rizatriptan—CYP1A2—blood—acquired immunodeficiency syndrome	0.000772	0.0203	CbGeAlD
Rizatriptan—HTR1D—brain—acquired immunodeficiency syndrome	0.000754	0.0198	CbGeAlD
Rizatriptan—MAOA—nervous system—acquired immunodeficiency syndrome	0.000751	0.0197	CbGeAlD
Rizatriptan—MAOA—central nervous system—acquired immunodeficiency syndrome	0.000723	0.019	CbGeAlD
Rizatriptan—CYP1A2—lung—acquired immunodeficiency syndrome	0.000677	0.0178	CbGeAlD
Rizatriptan—HTR1A—brain—acquired immunodeficiency syndrome	0.000628	0.0165	CbGeAlD
Rizatriptan—HTR1F—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000596	0.0187	CbGpPWpGaD
Rizatriptan—MAOA—brain—acquired immunodeficiency syndrome	0.000574	0.0151	CbGeAlD
Rizatriptan—MAOA—lymph node—acquired immunodeficiency syndrome	0.000555	0.0146	CbGeAlD
Rizatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.0005	0.0157	CbGpPWpGaD
Rizatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.00049	0.0153	CbGpPWpGaD
Rizatriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000474	0.0149	CbGpPWpGaD
Rizatriptan—HTR1F—GPCRs, Other—CCR5—acquired immunodeficiency syndrome	0.000459	0.0144	CbGpPWpGaD
Rizatriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000429	0.0134	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000381	0.0119	CbGpPWpGaD
Rizatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000373	0.0117	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000373	0.0117	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000361	0.0113	CbGpPWpGaD
Rizatriptan—HTR1F—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000333	0.0104	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000326	0.0102	CbGpPWpGaD
Rizatriptan—HTR1F—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000313	0.00981	CbGpPWpGaD
Rizatriptan—HTR1F—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000313	0.00981	CbGpPWpGaD
Rizatriptan—HTR1F—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000309	0.00968	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000306	0.00958	CbGpPWpGaD
Rizatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000303	0.0095	CbGpPWpGaD
Rizatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000297	0.0093	CbGpPWpGaD
Rizatriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000293	0.00917	CbGpPWpGaD
Rizatriptan—Hypertension—Ritonavir—acquired immunodeficiency syndrome	0.000292	0.000744	CcSEcCtD
Rizatriptan—Syncope—Saquinavir—acquired immunodeficiency syndrome	0.000292	0.000743	CcSEcCtD
Rizatriptan—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	0.000291	0.000742	CcSEcCtD
Rizatriptan—Tremor—Lamivudine—acquired immunodeficiency syndrome	0.000291	0.000741	CcSEcCtD
Rizatriptan—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.000291	0.00074	CcSEcCtD
Rizatriptan—HTR1F—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000291	0.00911	CbGpPWpGaD
Rizatriptan—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.00029	0.000739	CcSEcCtD
Rizatriptan—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.00029	0.000738	CcSEcCtD
Rizatriptan—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000289	0.000737	CcSEcCtD
Rizatriptan—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000289	0.000736	CcSEcCtD
Rizatriptan—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000289	0.000735	CcSEcCtD
Rizatriptan—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.000289	0.000735	CcSEcCtD
Rizatriptan—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	0.000288	0.000733	CcSEcCtD
Rizatriptan—Chest pain—Ritonavir—acquired immunodeficiency syndrome	0.000288	0.000733	CcSEcCtD
Rizatriptan—Myalgia—Ritonavir—acquired immunodeficiency syndrome	0.000288	0.000733	CcSEcCtD
Rizatriptan—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000287	0.000731	CcSEcCtD
Rizatriptan—Anxiety—Ritonavir—acquired immunodeficiency syndrome	0.000287	0.000731	CcSEcCtD
Rizatriptan—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	0.000286	0.000729	CcSEcCtD
Rizatriptan—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000285	0.000726	CcSEcCtD
Rizatriptan—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000285	0.000725	CcSEcCtD
Rizatriptan—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000285	0.000725	CcSEcCtD
Rizatriptan—Anorexia—Delavirdine—acquired immunodeficiency syndrome	0.000285	0.000725	CcSEcCtD
Rizatriptan—Discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000284	0.000725	CcSEcCtD
Rizatriptan—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000284	0.000724	CcSEcCtD
Rizatriptan—HTR1A—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000284	0.0089	CbGpPWpGaD
Rizatriptan—Cough—Saquinavir—acquired immunodeficiency syndrome	0.000284	0.000723	CcSEcCtD
Rizatriptan—Angioedema—Lamivudine—acquired immunodeficiency syndrome	0.000284	0.000723	CcSEcCtD
Rizatriptan—Pain—Indinavir—acquired immunodeficiency syndrome	0.000282	0.000719	CcSEcCtD
Rizatriptan—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000282	0.000719	CcSEcCtD
Rizatriptan—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.000282	0.000719	CcSEcCtD
Rizatriptan—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.000282	0.000718	CcSEcCtD
Rizatriptan—Convulsion—Saquinavir—acquired immunodeficiency syndrome	0.000282	0.000718	CcSEcCtD
Rizatriptan—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000282	0.000717	CcSEcCtD
Rizatriptan—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.000281	0.000716	CcSEcCtD
Rizatriptan—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000281	0.000715	CcSEcCtD
Rizatriptan—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000281	0.000715	CcSEcCtD
Rizatriptan—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.00028	0.000714	CcSEcCtD
Rizatriptan—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	0.00028	0.000713	CcSEcCtD
Rizatriptan—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000279	0.000712	CcSEcCtD
Rizatriptan—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000279	0.000712	CcSEcCtD
Rizatriptan—Vertigo—Lamivudine—acquired immunodeficiency syndrome	0.000279	0.000711	CcSEcCtD
Rizatriptan—Syncope—Lamivudine—acquired immunodeficiency syndrome	0.000278	0.000709	CcSEcCtD
Rizatriptan—Confusional state—Ritonavir—acquired immunodeficiency syndrome	0.000278	0.000709	CcSEcCtD
Rizatriptan—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000278	0.000708	CcSEcCtD
Rizatriptan—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.000277	0.000706	CcSEcCtD
Rizatriptan—Chest pain—Saquinavir—acquired immunodeficiency syndrome	0.000277	0.000706	CcSEcCtD
Rizatriptan—Myalgia—Saquinavir—acquired immunodeficiency syndrome	0.000277	0.000706	CcSEcCtD
Rizatriptan—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	0.000277	0.000706	CcSEcCtD
Rizatriptan—Anxiety—Saquinavir—acquired immunodeficiency syndrome	0.000276	0.000703	CcSEcCtD
Rizatriptan—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.000276	0.000703	CcSEcCtD
Rizatriptan—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000275	0.000701	CcSEcCtD
Rizatriptan—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.000275	0.000699	CcSEcCtD
Rizatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000274	0.00859	CbGpPWpGaD
Rizatriptan—Discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000274	0.000697	CcSEcCtD
Rizatriptan—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	0.000273	0.000695	CcSEcCtD
Rizatriptan—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.000272	0.000693	CcSEcCtD
Rizatriptan—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000272	0.000693	CcSEcCtD
Rizatriptan—Shock—Ritonavir—acquired immunodeficiency syndrome	0.000272	0.000692	CcSEcCtD
Rizatriptan—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.000271	0.000691	CcSEcCtD
Rizatriptan—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000271	0.00069	CcSEcCtD
Rizatriptan—Cough—Lamivudine—acquired immunodeficiency syndrome	0.000271	0.00069	CcSEcCtD
Rizatriptan—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000271	0.00069	CcSEcCtD
Rizatriptan—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000271	0.000689	CcSEcCtD
Rizatriptan—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.00027	0.000688	CcSEcCtD
Rizatriptan—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.00027	0.000688	CcSEcCtD
Rizatriptan—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.00027	0.000688	CcSEcCtD
Rizatriptan—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.000269	0.000686	CcSEcCtD
Rizatriptan—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000269	0.000686	CcSEcCtD
Rizatriptan—Convulsion—Lamivudine—acquired immunodeficiency syndrome	0.000269	0.000685	CcSEcCtD
Rizatriptan—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000269	0.000685	CcSEcCtD
Rizatriptan—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000269	0.000685	CcSEcCtD
Rizatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000268	0.00841	CbGpPWpGaD
Rizatriptan—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	0.000268	0.000683	CcSEcCtD
Rizatriptan—Confusional state—Saquinavir—acquired immunodeficiency syndrome	0.000268	0.000682	CcSEcCtD
Rizatriptan—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.000267	0.00068	CcSEcCtD
Rizatriptan—Pain—Efavirenz—acquired immunodeficiency syndrome	0.000267	0.000679	CcSEcCtD
Rizatriptan—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000267	0.000679	CcSEcCtD
Rizatriptan—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000267	0.000679	CcSEcCtD
Rizatriptan—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000267	0.000679	CcSEcCtD
Rizatriptan—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000266	0.000678	CcSEcCtD
Rizatriptan—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000266	0.000678	CcSEcCtD
Rizatriptan—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.000266	0.000677	CcSEcCtD
Rizatriptan—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.000265	0.000676	CcSEcCtD
Rizatriptan—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000265	0.000675	CcSEcCtD
Rizatriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000265	0.0083	CbGpPWpGaD
Rizatriptan—Myalgia—Lamivudine—acquired immunodeficiency syndrome	0.000264	0.000673	CcSEcCtD
Rizatriptan—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	0.000264	0.000673	CcSEcCtD
Rizatriptan—Chest pain—Lamivudine—acquired immunodeficiency syndrome	0.000264	0.000673	CcSEcCtD
Rizatriptan—Anxiety—Lamivudine—acquired immunodeficiency syndrome	0.000263	0.000671	CcSEcCtD
Rizatriptan—Anorexia—Ritonavir—acquired immunodeficiency syndrome	0.000263	0.00067	CcSEcCtD
Rizatriptan—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.000263	0.000669	CcSEcCtD
Rizatriptan—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.000262	0.000668	CcSEcCtD
Rizatriptan—Shock—Saquinavir—acquired immunodeficiency syndrome	0.000261	0.000666	CcSEcCtD
Rizatriptan—Discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000261	0.000665	CcSEcCtD
Rizatriptan—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000261	0.000665	CcSEcCtD
Rizatriptan—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.000261	0.000665	CcSEcCtD
Rizatriptan—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000261	0.000664	CcSEcCtD
Rizatriptan—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000261	0.000663	CcSEcCtD
Rizatriptan—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.00026	0.000661	CcSEcCtD
Rizatriptan—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	0.000259	0.000661	CcSEcCtD
Rizatriptan—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.000259	0.000659	CcSEcCtD
Rizatriptan—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000258	0.000658	CcSEcCtD
Rizatriptan—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000258	0.000657	CcSEcCtD
Rizatriptan—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000258	0.000656	CcSEcCtD
Rizatriptan—Rash—Stavudine—acquired immunodeficiency syndrome	0.000258	0.000656	CcSEcCtD
Rizatriptan—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000257	0.000655	CcSEcCtD
Rizatriptan—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000257	0.000655	CcSEcCtD
Rizatriptan—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.000257	0.000655	CcSEcCtD
Rizatriptan—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.000257	0.000654	CcSEcCtD
Rizatriptan—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000257	0.000654	CcSEcCtD
Rizatriptan—Headache—Stavudine—acquired immunodeficiency syndrome	0.000256	0.000652	CcSEcCtD
Rizatriptan—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000256	0.000652	CcSEcCtD
Rizatriptan—Confusional state—Lamivudine—acquired immunodeficiency syndrome	0.000256	0.000651	CcSEcCtD
Rizatriptan—Pain—Delavirdine—acquired immunodeficiency syndrome	0.000255	0.00065	CcSEcCtD
Rizatriptan—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000255	0.00065	CcSEcCtD
Rizatriptan—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.000255	0.00065	CcSEcCtD
Rizatriptan—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000255	0.000649	CcSEcCtD
Rizatriptan—Rash—Abacavir—acquired immunodeficiency syndrome	0.000254	0.000646	CcSEcCtD
Rizatriptan—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000253	0.000646	CcSEcCtD
Rizatriptan—Oedema—Lamivudine—acquired immunodeficiency syndrome	0.000253	0.000645	CcSEcCtD
Rizatriptan—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	0.000253	0.000645	CcSEcCtD
Rizatriptan—Anorexia—Saquinavir—acquired immunodeficiency syndrome	0.000253	0.000645	CcSEcCtD
Rizatriptan—Headache—Abacavir—acquired immunodeficiency syndrome	0.000252	0.000642	CcSEcCtD
Rizatriptan—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000251	0.00064	CcSEcCtD
Rizatriptan—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000251	0.00064	CcSEcCtD
Rizatriptan—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000251	0.00064	CcSEcCtD
Rizatriptan—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.00025	0.000636	CcSEcCtD
Rizatriptan—Shock—Lamivudine—acquired immunodeficiency syndrome	0.000249	0.000635	CcSEcCtD
Rizatriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000249	0.0078	CbGpPWpGaD
Rizatriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000249	0.0078	CbGpPWpGaD
Rizatriptan—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000249	0.000633	CcSEcCtD
Rizatriptan—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	0.000248	0.000631	CcSEcCtD
Rizatriptan—Urticaria—Efavirenz—acquired immunodeficiency syndrome	0.000248	0.000631	CcSEcCtD
Rizatriptan—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.000247	0.000628	CcSEcCtD
Rizatriptan—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.000247	0.000628	CcSEcCtD
Rizatriptan—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.000246	0.000627	CcSEcCtD
Rizatriptan—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	0.000246	0.000626	CcSEcCtD
Rizatriptan—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.000245	0.000625	CcSEcCtD
Rizatriptan—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	0.000245	0.000624	CcSEcCtD
Rizatriptan—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.000244	0.000622	CcSEcCtD
Rizatriptan—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000243	0.00062	CcSEcCtD
Rizatriptan—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.000243	0.00062	CcSEcCtD
Rizatriptan—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	0.000243	0.000619	CcSEcCtD
Rizatriptan—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000243	0.000619	CcSEcCtD
Rizatriptan—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000243	0.000618	CcSEcCtD
Rizatriptan—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000242	0.000616	CcSEcCtD
Rizatriptan—Anorexia—Lamivudine—acquired immunodeficiency syndrome	0.000242	0.000615	CcSEcCtD
Rizatriptan—Insomnia—Saquinavir—acquired immunodeficiency syndrome	0.00024	0.000612	CcSEcCtD
Rizatriptan—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	0.00024	0.000611	CcSEcCtD
Rizatriptan—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000239	0.000609	CcSEcCtD
Rizatriptan—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	0.000239	0.000608	CcSEcCtD
Rizatriptan—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000238	0.000607	CcSEcCtD
Rizatriptan—HTR1F—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000238	0.00746	CbGpPWpGaD
Rizatriptan—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.000238	0.000606	CcSEcCtD
Rizatriptan—Urticaria—Delavirdine—acquired immunodeficiency syndrome	0.000237	0.000604	CcSEcCtD
Rizatriptan—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000237	0.000603	CcSEcCtD
Rizatriptan—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.000237	0.000603	CcSEcCtD
Rizatriptan—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.000236	0.000602	CcSEcCtD
Rizatriptan—Pain—Ritonavir—acquired immunodeficiency syndrome	0.000236	0.000601	CcSEcCtD
Rizatriptan—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000236	0.000601	CcSEcCtD
Rizatriptan—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.000236	0.000601	CcSEcCtD
Rizatriptan—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.000236	0.000601	CcSEcCtD
Rizatriptan—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000235	0.000598	CcSEcCtD
Rizatriptan—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	0.000234	0.000596	CcSEcCtD
Rizatriptan—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000234	0.000595	CcSEcCtD
Rizatriptan—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	0.000231	0.000588	CcSEcCtD
Rizatriptan—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000231	0.000588	CcSEcCtD
Rizatriptan—HTR1D—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000231	0.00723	CbGpPWpGaD
Rizatriptan—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.00023	0.000585	CcSEcCtD
Rizatriptan—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000229	0.000584	CcSEcCtD
Rizatriptan—Insomnia—Lamivudine—acquired immunodeficiency syndrome	0.000229	0.000584	CcSEcCtD
Rizatriptan—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.000229	0.000583	CcSEcCtD
Rizatriptan—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	0.000228	0.00058	CcSEcCtD
Rizatriptan—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	0.000227	0.000579	CcSEcCtD
Rizatriptan—Pain—Saquinavir—acquired immunodeficiency syndrome	0.000227	0.000579	CcSEcCtD
Rizatriptan—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000227	0.000579	CcSEcCtD
Rizatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000226	0.00708	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000226	0.00708	CbGpPWpGaD
Rizatriptan—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.000226	0.000575	CcSEcCtD
Rizatriptan—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000226	0.000575	CcSEcCtD
Rizatriptan—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000226	0.000575	CcSEcCtD
Rizatriptan—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.000226	0.000575	CcSEcCtD
Rizatriptan—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.000225	0.000574	CcSEcCtD
Rizatriptan—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000224	0.00057	CcSEcCtD
Rizatriptan—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000224	0.00057	CcSEcCtD
Rizatriptan—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000224	0.00057	CcSEcCtD
Rizatriptan—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	0.000223	0.000568	CcSEcCtD
Rizatriptan—HTR1F—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000223	0.00699	CbGpPWpGaD
Rizatriptan—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000222	0.000566	CcSEcCtD
Rizatriptan—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000221	0.000562	CcSEcCtD
Rizatriptan—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	0.00022	0.000561	CcSEcCtD
Rizatriptan—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.00022	0.00056	CcSEcCtD
Rizatriptan—Urticaria—Ritonavir—acquired immunodeficiency syndrome	0.000219	0.000558	CcSEcCtD
Rizatriptan—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	0.000219	0.000558	CcSEcCtD
Rizatriptan—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000219	0.000557	CcSEcCtD
Rizatriptan—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.000219	0.000556	CcSEcCtD
Rizatriptan—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000218	0.000556	CcSEcCtD
Rizatriptan—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.000218	0.000556	CcSEcCtD
Rizatriptan—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	0.000218	0.000556	CcSEcCtD
Rizatriptan—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.000217	0.000553	CcSEcCtD
Rizatriptan—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000217	0.000552	CcSEcCtD
Rizatriptan—Pain—Lamivudine—acquired immunodeficiency syndrome	0.000217	0.000552	CcSEcCtD
Rizatriptan—HTR1F—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000215	0.00672	CbGpPWpGaD
Rizatriptan—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.000214	0.000545	CcSEcCtD
Rizatriptan—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000213	0.000544	CcSEcCtD
Rizatriptan—HTR1D—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000213	0.00667	CbGpPWpGaD
Rizatriptan—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000211	0.000538	CcSEcCtD
Rizatriptan—Urticaria—Saquinavir—acquired immunodeficiency syndrome	0.000211	0.000538	CcSEcCtD
Rizatriptan—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000211	0.000537	CcSEcCtD
Rizatriptan—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.00021	0.000535	CcSEcCtD
Rizatriptan—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	0.00021	0.000535	CcSEcCtD
Rizatriptan—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.00021	0.000535	CcSEcCtD
Rizatriptan—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	0.000209	0.000532	CcSEcCtD
Rizatriptan—HTR1D—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000209	0.00654	CbGpPWpGaD
Rizatriptan—HTR1B—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000209	0.00653	CbGpPWpGaD
Rizatriptan—Rash—Indinavir—acquired immunodeficiency syndrome	0.000208	0.00053	CcSEcCtD
Rizatriptan—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000208	0.00053	CcSEcCtD
Rizatriptan—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	0.000207	0.000528	CcSEcCtD
Rizatriptan—Headache—Indinavir—acquired immunodeficiency syndrome	0.000207	0.000527	CcSEcCtD
Rizatriptan—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000206	0.000525	CcSEcCtD
Rizatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000204	0.00641	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000204	0.0064	CbGpPWpGaD
Rizatriptan—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000204	0.00052	CcSEcCtD
Rizatriptan—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.000203	0.000518	CcSEcCtD
Rizatriptan—HTR1F—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000202	0.00632	CbGpPWpGaD
Rizatriptan—Urticaria—Lamivudine—acquired immunodeficiency syndrome	0.000201	0.000513	CcSEcCtD
Rizatriptan—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.0002	0.00051	CcSEcCtD
Rizatriptan—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	0.0002	0.00051	CcSEcCtD
Rizatriptan—HTR1D—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.0002	0.00627	CbGpPWpGaD
Rizatriptan—HTR1D—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.0002	0.00627	CbGpPWpGaD
Rizatriptan—HTR1F—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000199	0.00624	CbGpPWpGaD
Rizatriptan—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000198	0.000505	CcSEcCtD
Rizatriptan—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000198	0.000504	CcSEcCtD
Rizatriptan—HTR1D—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000198	0.00619	CbGpPWpGaD
Rizatriptan—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000197	0.000503	CcSEcCtD
Rizatriptan—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000197	0.000501	CcSEcCtD
Rizatriptan—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000197	0.0005	CcSEcCtD
Rizatriptan—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000196	0.000499	CcSEcCtD
Rizatriptan—HTR1B—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000196	0.00614	CbGpPWpGaD
Rizatriptan—HTR1B—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000196	0.00614	CbGpPWpGaD
Rizatriptan—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.000196	0.000498	CcSEcCtD
Rizatriptan—HTR1D—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000196	0.00613	CbGpPWpGaD
Rizatriptan—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000195	0.000498	CcSEcCtD
Rizatriptan—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000195	0.000497	CcSEcCtD
Rizatriptan—HTR1B—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000194	0.00606	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000191	0.006	CbGpPWpGaD
Rizatriptan—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000191	0.000485	CcSEcCtD
Rizatriptan—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.00019	0.000483	CcSEcCtD
Rizatriptan—HTR1F—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.00019	0.00594	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.00019	0.00594	CbGpPWpGaD
Rizatriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000189	0.00593	CbGpPWpGaD
Rizatriptan—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.000189	0.000481	CcSEcCtD
Rizatriptan—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000188	0.000479	CcSEcCtD
Rizatriptan—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000188	0.000479	CcSEcCtD
Rizatriptan—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000188	0.000479	CcSEcCtD
Rizatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000187	0.00587	CbGpPWpGaD
Rizatriptan—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000187	0.000476	CcSEcCtD
Rizatriptan—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.000187	0.000476	CcSEcCtD
Rizatriptan—HTR1D—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000186	0.00582	CbGpPWpGaD
Rizatriptan—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000185	0.000472	CcSEcCtD
Rizatriptan—HTR1F—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000185	0.0058	CbGpPWpGaD
Rizatriptan—MAOA—SIDS Susceptibility Pathways—IL10—acquired immunodeficiency syndrome	0.000185	0.00579	CbGpPWpGaD
Rizatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000183	0.00575	CbGpPWpGaD
Rizatriptan—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000183	0.000465	CcSEcCtD
Rizatriptan—HTR1B—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000182	0.0057	CbGpPWpGaD
Rizatriptan—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.000182	0.000463	CcSEcCtD
Rizatriptan—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.000182	0.000463	CcSEcCtD
Rizatriptan—HTR1F—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000181	0.00566	CbGpPWpGaD
Rizatriptan—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.000179	0.000457	CcSEcCtD
Rizatriptan—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000177	0.000452	CcSEcCtD
Rizatriptan—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000176	0.000447	CcSEcCtD
Rizatriptan—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000176	0.000447	CcSEcCtD
Rizatriptan—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000174	0.000443	CcSEcCtD
Rizatriptan—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000174	0.000443	CcSEcCtD
Rizatriptan—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000173	0.000442	CcSEcCtD
Rizatriptan—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000173	0.00044	CcSEcCtD
Rizatriptan—HTR1A—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000172	0.00539	CbGpPWpGaD
Rizatriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000171	0.00535	CbGpPWpGaD
Rizatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000169	0.00531	CbGpPWpGaD
Rizatriptan—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000169	0.00043	CcSEcCtD
Rizatriptan—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000168	0.000427	CcSEcCtD
Rizatriptan—HTR1F—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000168	0.00525	CbGpPWpGaD
Rizatriptan—Rash—Saquinavir—acquired immunodeficiency syndrome	0.000168	0.000427	CcSEcCtD
Rizatriptan—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.000167	0.000426	CcSEcCtD
Rizatriptan—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000166	0.000424	CcSEcCtD
Rizatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000166	0.0052	CbGpPWpGaD
Rizatriptan—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000164	0.000418	CcSEcCtD
Rizatriptan—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000161	0.00041	CcSEcCtD
Rizatriptan—Rash—Lamivudine—acquired immunodeficiency syndrome	0.00016	0.000407	CcSEcCtD
Rizatriptan—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.00016	0.000407	CcSEcCtD
Rizatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000159	0.00499	CbGpPWpGaD
Rizatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000159	0.00499	CbGpPWpGaD
Rizatriptan—HTR1A—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000159	0.00498	CbGpPWpGaD
Rizatriptan—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000159	0.000404	CcSEcCtD
Rizatriptan—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000158	0.000402	CcSEcCtD
Rizatriptan—HTR1A—SIDS Susceptibility Pathways—IL10—acquired immunodeficiency syndrome	0.000157	0.00492	CbGpPWpGaD
Rizatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000156	0.00488	CbGpPWpGaD
Rizatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000156	0.00488	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000156	0.00488	CbGpPWpGaD
Rizatriptan—HTR1D—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000152	0.00477	CbGpPWpGaD
Rizatriptan—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000151	0.000383	CcSEcCtD
Rizatriptan—HTR1A—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000149	0.00468	CbGpPWpGaD
Rizatriptan—HTR1A—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000149	0.00468	CbGpPWpGaD
Rizatriptan—HTR1B—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000149	0.00467	CbGpPWpGaD
Rizatriptan—HTR1A—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000147	0.00462	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000146	0.00457	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000144	0.00452	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000143	0.00447	CbGpPWpGaD
Rizatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.00014	0.00438	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.00014	0.00437	CbGpPWpGaD
Rizatriptan—HTR1A—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000139	0.00434	CbGpPWpGaD
Rizatriptan—HTR1D—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000137	0.0043	CbGpPWpGaD
Rizatriptan—HTR1B—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000134	0.00421	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.00013	0.00407	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000129	0.00404	CbGpPWpGaD
Rizatriptan—HTR1D—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000127	0.00399	CbGpPWpGaD
Rizatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000126	0.00396	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000126	0.00396	CbGpPWpGaD
Rizatriptan—HTR1B—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000125	0.00391	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000121	0.0038	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000121	0.0038	CbGpPWpGaD
Rizatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000121	0.0038	CbGpPWpGaD
Rizatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000119	0.00372	CbGpPWpGaD
Rizatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000119	0.00372	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000119	0.00372	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000119	0.00372	CbGpPWpGaD
Rizatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000119	0.00372	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000118	0.00371	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000116	0.00363	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000116	0.00362	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000114	0.00359	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000114	0.00357	CbGpPWpGaD
Rizatriptan—HTR1A—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000114	0.00356	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000113	0.00354	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000109	0.00343	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000109	0.00343	CbGpPWpGaD
Rizatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000109	0.00342	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—TAT—acquired immunodeficiency syndrome	0.000108	0.00338	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000107	0.00336	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000107	0.00336	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000107	0.00336	CbGpPWpGaD
Rizatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000107	0.00335	CbGpPWpGaD
Rizatriptan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—acquired immunodeficiency syndrome	0.000106	0.00334	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000106	0.00333	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000105	0.00329	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000104	0.00324	CbGpPWpGaD
Rizatriptan—HTR1A—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000102	0.00321	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	9.9e-05	0.0031	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	9.73e-05	0.00305	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	9.73e-05	0.00305	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	9.62e-05	0.00301	CbGpPWpGaD
Rizatriptan—HTR1A—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	9.5e-05	0.00298	CbGpPWpGaD
Rizatriptan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—acquired immunodeficiency syndrome	9.46e-05	0.00296	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	9.23e-05	0.00289	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—AGPS—acquired immunodeficiency syndrome	9.19e-05	0.00288	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	9.05e-05	0.00283	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	9.05e-05	0.00283	CbGpPWpGaD
Rizatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	9.04e-05	0.00283	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	9.03e-05	0.00283	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	8.84e-05	0.00277	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	8.62e-05	0.0027	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	8.31e-05	0.0026	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	8.15e-05	0.00255	CbGpPWpGaD
Rizatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	8.14e-05	0.00255	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	8.14e-05	0.00255	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	8.03e-05	0.00252	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	7.99e-05	0.0025	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	7.61e-05	0.00238	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	7.4e-05	0.00232	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	7.34e-05	0.0023	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	7.32e-05	0.00229	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	7.29e-05	0.00228	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	7.29e-05	0.00228	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	7.17e-05	0.00225	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	7.14e-05	0.00224	CbGpPWpGaD
Rizatriptan—MAOA—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	7.04e-05	0.0022	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	7e-05	0.00219	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	7e-05	0.00219	CbGpPWpGaD
Rizatriptan—CYP1A2—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	6.89e-05	0.00216	CbGpPWpGaD
Rizatriptan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	6.89e-05	0.00216	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	6.88e-05	0.00216	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	6.85e-05	0.00215	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	6.85e-05	0.00215	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	6.85e-05	0.00215	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	6.85e-05	0.00215	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	6.76e-05	0.00212	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	6.71e-05	0.0021	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	6.71e-05	0.0021	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	6.67e-05	0.00209	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	6.62e-05	0.00207	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	6.48e-05	0.00203	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	6.33e-05	0.00198	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	6.22e-05	0.00195	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	6.22e-05	0.00195	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	6.2e-05	0.00194	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	6.2e-05	0.00194	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	6.11e-05	0.00192	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	6.09e-05	0.00191	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	6.09e-05	0.00191	CbGpPWpGaD
Rizatriptan—HTR1A—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	5.98e-05	0.00187	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	5.75e-05	0.0018	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	5.75e-05	0.0018	CbGpPWpGaD
Rizatriptan—MAOA—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	5.68e-05	0.00178	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	5.46e-05	0.00171	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	5.44e-05	0.0017	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	5.22e-05	0.00164	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	5.22e-05	0.00164	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	5.21e-05	0.00163	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	5.14e-05	0.00161	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	5.11e-05	0.0016	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	5.11e-05	0.0016	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	5.1e-05	0.0016	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	5.03e-05	0.00158	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	4.94e-05	0.00155	CbGpPWpGaD
Rizatriptan—HTR1A—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	4.83e-05	0.00151	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	4.73e-05	0.00148	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.72e-05	0.00148	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	4.7e-05	0.00147	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	4.66e-05	0.00146	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.64e-05	0.00145	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.64e-05	0.00145	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	4.64e-05	0.00145	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	4.6e-05	0.00144	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	4.57e-05	0.00143	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	4.37e-05	0.00137	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.32e-05	0.00135	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	4.31e-05	0.00135	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	4.27e-05	0.00134	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	4.24e-05	0.00133	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.23e-05	0.00133	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	4.18e-05	0.00131	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—TAT—acquired immunodeficiency syndrome	3.98e-05	0.00125	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.94e-05	0.00123	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.91e-05	0.00122	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.89e-05	0.00122	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.85e-05	0.00121	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.83e-05	0.0012	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.83e-05	0.0012	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.68e-05	0.00115	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.68e-05	0.00115	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.6e-05	0.00113	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.6e-05	0.00113	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.53e-05	0.00111	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.5e-05	0.0011	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.48e-05	0.00109	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—AGPS—acquired immunodeficiency syndrome	3.39e-05	0.00106	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.22e-05	0.00101	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.18e-05	0.000997	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.92e-05	0.000914	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.8e-05	0.000876	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.75e-05	0.000863	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.74e-05	0.000859	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.74e-05	0.000859	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.74e-05	0.000858	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.71e-05	0.00085	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.7e-05	0.000845	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.66e-05	0.000832	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.52e-05	0.000789	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.47e-05	0.000773	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.46e-05	0.000772	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.41e-05	0.000756	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.28e-05	0.000713	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.27e-05	0.00071	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.09e-05	0.000654	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.05e-05	0.000644	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.02e-05	0.000634	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—ALB—acquired immunodeficiency syndrome	1.88e-05	0.00059	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.88e-05	0.000589	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.84e-05	0.000576	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.56e-05	0.000489	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.46e-05	0.000456	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.45e-05	0.000454	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.43e-05	0.000447	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.42e-05	0.000444	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.34e-05	0.000419	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.09e-05	0.00034	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.08e-05	0.000338	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.56e-06	0.000268	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.38e-06	0.000262	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—ALB—acquired immunodeficiency syndrome	6.95e-06	0.000218	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.38e-06	0.0002	CbGpPWpGaD
